secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024980
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports Q3 net loss $10.5M; advances tegoprubart with FDA IND clearances
-------------------------------------------------------------------------------

- Net loss of $10.5M ($0.73/share) vs $9.8M ($0.66/share) in Q3 2021.
- Cash and equivalents $65.9M as of Sep 30, 2022; runway into 2024.
- FDA cleared IND for Phase 2 trial of tegoprubart in kidney transplant prevention.
- FDA cleared IND for tegoprubart in IgA Nephropathy; global Phase 2a enrolling.
- Initial data from kidney, islet cell, and IgAN studies expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/0000950170-22-024980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/eldn-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer